Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments Aug 9, 2024
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr Jul 9, 2024
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24 Jun 25, 2024
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting Jun 10, 2024
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline May 9, 2024
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting Apr 18, 2024
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings Apr 16, 2024
